Molecular Biomarkers & Diagnosis

Marion Compagnone

Publications

• Research Article
  Comparison of Standardized Approaches in Detecting EGFR, KRAS and BRAF Mutations
  Author(s): Marion Compagnone, Philippe Halfon and Sylviane OlschwangMarion Compagnone, Philippe Halfon and Sylviane Olschwang
  
  Background: EGFR tyrosine-kinase inhibitors have shown efficacy in non-small-cell lung cancer (NSCLC) with specific EGFR mutations. The impact of KRAS and BRAF mutations on therapeutic response remains under evaluation. The study aimed validating the use of mutation detection kits in a routine laboratory. Methods: The mutation status of the EGFR, KRAS and BRAF genes, previously determined by Sanger sequencing, was analyzed with two approaches, pyrosequencing (Therascreen® Pyro® kits) and allele specific amplification (Cobas® mutation tests). A set of 70 DNAs from NSCLC tissue samples was selected and harboured 7 EGFR, 3 KRAS and 4 BRAF mutations. Results: The Cobas® kit missed one EGFR and all BRAF mutations, and the Therascreen® kit missed one KRAS and 2 BRAF mutations. The Cobas® kit run i.. Read More»
  DOI: 10.4172/2155-9929.1000220

  Abstract PDF